Compare NWGL & GANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NWGL | GANX |
|---|---|---|
| Founded | 2008 | 2017 |
| Country | Macau | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 19.6M | 78.2M |
| IPO Year | 2022 | 2021 |
| Metric | NWGL | GANX |
|---|---|---|
| Price | $0.79 | $1.78 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $7.50 |
| AVG Volume (30 Days) | 82.9K | ★ 507.4K |
| Earning Date | 05-21-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 31.46 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $55,180.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.61 | $1.41 |
| 52 Week High | $6.61 | $4.34 |
| Indicator | NWGL | GANX |
|---|---|---|
| Relative Strength Index (RSI) | 42.96 | 46.62 |
| Support Level | $0.75 | $1.73 |
| Resistance Level | $1.47 | $2.09 |
| Average True Range (ATR) | 0.09 | 0.10 |
| MACD | -0.00 | -0.00 |
| Stochastic Oscillator | 31.52 | 62.50 |
CL Workshop Group Ltd, formerly Nature Wood Group Ltd is a vertically-integrated forestry company that focuses on FSC business operations. It produces various products, including logs, decking, flooring, sawn timber, recycled charcoal, synthesized charcoal, machine-made charcoal, and essential oils. The Group owns natural forest concessions and cutting rights for exploiting timbers on parcels of land in Peru. The Group is organized into two operating divisions; Direct Purchase and Original Design Manufacturer (ODM) Services, and Manufacturing segments. The Direct Purchase and ODM Segment that derives the majority of revenue engages in the business of sourcing live wood and owning designed designs on wood products for sales to end customers.
Gain Therapeutics Inc is a clinical-stage biotechnology company developing novel small-molecule therapeutics to treat diseases across several therapeutic areas, including central nervous system (CNS) disorders, lysosomal storage disorders (LSDs), metabolic disorders, and other diseases that can be targeted through protein degradation, such as oncology. The Company's clinical stage product candidate, GT-02287, is being developed for the treatment of Parkinson's disease with and without GBA1 mutations. The Company generated an extensive preclinical data package providing evidence of the mechanism of action.